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Nick Glozier1 and Patrick D McGorry6,7Abstract
Background: After 30 years of consensus-derived diagnostic categories in mental health, it is time to head in new
directions. Those categories placed great emphasis on enhanced reliability and the capacity to identify them via
standardized checklists. Although this enhanced epidemiology and health services planning, it failed to link broad
diagnostic groupings to underlying pathophysiology or specific treatment response.
Discussion: It is time to adopt new goals that prioritize the validation of clinical entities and foster alternative
strategies to support those goals. The value of new dimensions (notably clinical staging), that are both clinically
relevant and directly related to emerging developmental and neurobiological research, is proposed. A strong
emphasis on ‘reverse translation’ (that is, working back from the clinic to the laboratory) underpins these novel
approaches. However, it relies on using diagnostic groupings that already have strong evidence of links to specific
risk factors or patterns of treatment response.
Summary: The strategies described abandon the historical divides between clinical neurology, psychiatry and
psychology and adopt the promotion of pathways to illness models.
Keywords: Classification, Clinical staging, Mental healthBackground
Globally, the biggest challenge in public mental health is
implementing strategies to reduce the societal burden of
mental disorders [1,2]. For those living with mental illness
and their families, the most pressing issues are increasing
access to affordable health care, promoting social inclu-
sion, supporting economic productivity and reducing pre-
mature mortality [1-4]. From a clinical perspective, our
greatest failure has been the lack of development of new
or better-targeted treatments, particularly for those with
persisting and disabling disorders. Additionally, our inabil-
ity to predict individual responses to treatments and our
failure to intervene early to reduce disability or prevent
premature death are notable [5-10].
Despite the degree of public or media attention [11-13],
deciding the immediate fate of our major international clas-
sification systems is not our most central task. It is timely,
however, to reflect on the Diagnostic and Statistical Manual* Correspondence: ian.hickie@sydney.edu.au
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reproduction in any medium, provided the or(DSM) for Mental Disorders, fourth edition [14] and the
closely related International Classification of Diseases, 10th
revision (ICD-10) [15]. The application of these systems has
improved the reliability of syndromal (symptom-based)
diagnoses as used in psychiatry, but these remain inferior to
the evidence-based etiological or pathway models employed
for other common medical conditions.
After 30 years of clinical research, which is based on a
common set of principles, our diagnostic entities remain
poorly validated. That is, despite the research explosion in
basic neuroscience, imaging and molecular genetics, our
categories do not link strongly to any specific neurobio-
logical or environmental risk factors, underlying patho-
physiological processes, or patterns of specific treatment
response [5,6,16-18]. Consequently, our classification sys-
tems have arrived at a fundamental cross-road.
While the DSM processes seem set to continue down
familiar paths [19], it is timely to consider whether cli-
nical psychiatry and psychology would be better served
by heading in somewhat different directions [20-26].
Here, we explore specific alternatives including a much
greater fusion of classification systems with other areastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sures of behavioral and cognitive change, the adoption
of a limited number of pathophysiologically based syn-
dromes that incorporate objective testing, a greater reli-
ance on implications of response to specific treatments,
and the extent to which incorporation of a common
general medical concept - namely, clinical staging - rep-
resents a major advance [27,28]. Most importantly, we
suggest that such alternatives take us a much greater
way along the path to enhanced treatment planning.
The clinical challenge
It is frustrating that diagnoses are based largely on de-
scriptive phenomena. Often they vary from practitioner
to practitioner, and may well change markedly over the
course of illness (for example, non-psychotic to psy-
chotic syndrome or unipolar to bipolar mood disorder).
As diagnoses are made at non-specific time points along
complex illness pathways that evolve from risk to onset
and progression to chronic ill-health, they often relate
poorly to the actual stage of illness. For the major an-
xiety, mood or psychotic disorders, the illness process
typically has its onset in late childhood or early puberty
and then recurs or continues progressively into adult life
[29-31]. Although 75% of major mental disorders begin
before the age of 25 years [32], our diagnostic criteria
are derived largely from the experiences reported by
middle-aged persons with established illness. These phe-
notypes often map poorly onto earlier and often less
specific phases of the illness experience [22,25,33,34].
The current systems also assume the concept of mul-
tiple parallel pathways each leading to distinct diagnostic
categories - an assumption that is not readily supported
by modern family, genetic and neurobiological risk factor
studies [20,35,36]. Criterion-based symptom sets (which
then give rise to specific and ‘independent’ categories)
prioritize phenomena such as delusions, hallucinations,
periods of elevated mood or increased energy, psychomo-
tor slowing, emotional blunting, or cognitive slowing for
disorders such as schizophrenia, bipolar disorder or severe
depression. Data from recent community studies that as-
sess patients longitudinally from childhood or adolescence
[29,37-39], however, emphasize the extent to which many
of these phenomena are shared across disorders [40].
Prototypically, anxiety disorders that are evident in chil-
dren before the age of 12 years predict later depressive, bi-
polar and psychotic disorders [41].
With regards to adult-type disorders, persistence or re-
currence of symptoms appears to have greater predictive
significance than cross-sectional observation of specific
symptoms [39,42-45]. Hence, the great clinical challenge is
to derive new diagnostic systems that are not only consis-
tent with developmental epidemiology and neurobiology
but also useful when applied in everyday clinical practice.A historical perspective
The great virtue of the research-based classification sys-
tems of the late 1970s was that they promoted the pursuit
of reliable diagnoses. To achieve diagnostic reliability, a
small number of dimensions in human behavior (for ex-
ample, anxiety, depression, impaired cognition or psych-
otic phenomena) were organized into a large number of
discrete and separate ‘disorders’ - on the basis of the pres-
ence or absence of set numbers of key symptoms. Inevi-
tably, this gave rise to a checklist approach to diagnostic
practice and the proliferation of diagnostic ‘categories’.
However, reliability was oversold as the necessary pre-
cursor to validation of those entities [16]. While the
‘atheoretical’ and reliability-driven approach of DSM-III
did set clinical research free from the previous psycho-
logical, behavioral or medical models, it did not result in
a new era of preventive and therapeutic strategies. In
retrospect, it appears that the DSM-III-derived disorders
or independent categories relied too heavily on descrip-
tive psychopathology, historical practice or clinical con-
sensus [46,47].
The post-DSM-III era did enhance our capacity to
conduct large, multi-site and international research and
ensured that diagnostic concepts were less constrained
by local history, culture, religion or social customs, or
fashion. Such aspirations were essential to promoting
the international ‘science’ base of clinical psychiatry and
psychology and for forging links to key areas of emer-
ging neuroscience, especially molecular genetics and
neuroimaging. Further, this greatly assisted the move
away from highly idiosyncratic practice or ‘diagnostic
systems’ that were used to prop up the delivery of poorly
evaluated (or intrinsically harmful or discriminatory)
forms of mental health care. Mental health practice is
one area of social endeavor that has benefited greatly
from globalization and greater transparency, communi-
cation and scrutiny [2].
When linked to national epidemiological surveys, the
international classification systems have underpinned
more accurate estimates of relative disease burden, access
to care and impacts of mental disorders on broader health
and social systems [1,32,48]. This has led to more forward
thinking about how to best support broad social settings
that enhance mental health and wellbeing [49]. Thus, in
many ways, the great successes of the post-DSM-III diag-
nostic era are in public health and related health system
developments. It is rather frustrating that, despite the best
efforts of scientists and practitioners, the stated aims of
advancing clinical research have not been so successful.
Discussion
Setting new goals for international classification systems
Given the relative failure to validate the DSM- or ICD-
derived categories, it is time to set new goals (Table 1) -
Table 1 New goals for enhanced diagnostic categories and worked examples for major depression
Clear goals Consequences for diagnoses related to major depression
1. Focus primarily on enhancing clinical
practice
1. Abandon use of the single term ‘major depression’ as on its own it does not predict
response to specific psychological or physical treatments [62];
2. Only use in association with specifiers that predict likely response to specific treatments -
for example, major depression with psychotic features; melancholia associated with
psychomotor changes [63-65]; depression following manic episode [62];
3. Differentiate other risk or comorbidity factors from the diagnosis itself - notably risk of self-
harm or suicide or misuse of alcohol and other substances [66-69].
2. Link directly to objective markers of
pathophysiological processes
Require the cross-sectional and longitudinal recording of objective markers that may predict
response to treatment or risk of recurrence:
• Neurohormonal - for example, presence of non-suppression to dexamethasone [70];
• Circadian or sleep - for example, actigraphic evidence of phase-delay [58,60,71];
• Psychomotor change - for example, observer or automated measures [63-65];
• Neuropsychological - for example, neuropsychological evidence of delayed reaction time
[72-75];
• Brain imaging - for example, presence of subcortical white matter changes [59,74,76-82].
3. Incorporate known facts about
developmental paths, environmental risk
factors, course of illness or family history
1. Differentiate early-onset (<30 years) from late-onset (>50 years) forms [83-87];
2. Differentiate first major episode from recurrence, relapse or chronicity [21,22,52,88];
3. Record clear environmental (for example, seasonal onset, exposure to traumatic events) or
medical illness (for example, post-stroke) exposures that are concurrent with depression [89];
4. Record clear earlier (notably childhood) phenotypes such as childhood anxiety;
5. Record clear family history data related to presence of psychosis, mania or suicide in first-
degree relatives [35,37,90-95];
6. Record clear history of exposure to social adversity or interpersonal stressors or ongoing
evidence of major socio-economic, interpersonal or other relevant social circumstances
[96-98].
4. Be consistent with data from family, twin
or genetic studies
1. Restrict the diagnosis to those sub-categories with strong evidence of high heritability -
for example, depression in those with previous mania; depression in those with psychotic
features [35,37,38,99-101];
2. Support the concepts of depressive disorders preceded by childhood anxiety or early-
versus late-onset depressive disorders [66,84-86,102].
5. Capture key aspects of illness stage Use a clinical staging format for depressive disorders that differentiates early stages that are
strongly linked to other childhood and adolescent phenotypes (for example, anxiety, phase-
delay in sleep and circadian systems, fatigue, hypomania, mood instability) from later early
adult or mid-adult stages (which may also be associated with different phenotypes such as
psychomotor change, phase-advance in sleep and circadian systems) [21,22,58-61,88,102].
6. Best predict future illness course or
response to specific treatments.
Use known factors about response/non-response to specific treatments - for example, for
acute episode: classify as selective serotonin reuptake inhibitor responder or non-responder;
classify as responder or non-responder to cognitive behavioral therapy [103-105].
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strategies to support those goals (Table 2). An over-
riding concern in mental health has become the reduction
of the population-health burden by adoption of various
early intervention strategies [28,50,51]. These focus clin-
ical service development and related research on
identifying early forms of illness not only to reduce
current morbidity but also to prevent progression to
more severe or chronic illness types and associated
role impairment [52-57]. Although the fundamental
empirical work in this area has focused largely on
psychotic disorders, there is now a much broader
clinical database emerging that is targeted at the early
phases of the more prevalent anxiety and depressive
disorders [22,53,58-61].This movement is similar in conceptualization with
that being promoted in other related clinical areas of
medicine that have very large impacts on current and
future health costs, notably diabetes and related meta-
bolic syndromes [125-127]. As with the move to define
pre-diabetes (an intermediate state between normal and
clearly raised blood glucose concentrations), it is en-
tirely possible to define emerging mental disorders by
their intermediate symptom levels, impacts on function,
patterns of persistence over time or predictive capacity
[21,22,56,57]. Further, it is possible to design new health
care platforms to increase the access to care for young
people presenting with these conditions [53,55].
Importantly, the same types of concerns arise in the
arenas for both pre-diabetes and early intervention in
Table 2 New strategies for deriving diagnostic categories and worked examples for major depression
New strategies Implications for major depression
1. Abandon the artificial distinction between
brain (neurological) and psychiatric or
psychological (mental) disorders
1. Focus clinical attention on the broad affective, cognitive, motor and sleep or circadian
aspects of significant depressive disorders [58-61,72,106];
2. Encourage systematic cross-sectional and longitudinal structural brain imaging across
the various phases of early- and late-onset depressive disorders [78,83].
2. Avoid the use of single categorical states
(for example, major depression,
schizophrenia, bipolar disorder) that
describe heterogeneous groups
Only use major depression in association with specific descriptors including early- versus
late-onset, preceded by childhood anxiety; comorbid with alcohol or other substance
misuse, significant circadian disturbance, psychotic features, significant psychomotor
disturbance or other discrete melancholic features [61,63-65,78,84,107-110].
3. Promote pathways to illness models that
have a strong basis in longitudinal
epidemiology and related risk factor or
neuroscience research
Promote categories such as depression preceded by childhood anxiety; childhood
traumatic events; depression associated with significant circadian disturbance; depression
associated with psychomotor change; depression following a clear manic episode [61].
4. Incorporate age-of-onset and stage-of
-illness concepts into all diagnostic
processes
1. For depression, the first age of a clear depressive syndrome would be recorded, as
well as the first clear episode of sufficient severity to justify intervention [66,111,112];
2. For depression, the clear pattern of remission, relapse or recovery would be recorded
for all patients [113].
5. Reduce the concept of comorbidity to
the co-occurrence of genuinely
independent conditions
1. Depression occurring in association with documented diabetes or cardiovascular
disease [114-119];
2. Rejecting the notion of anxiety and depression representing comorbid conditions, as
distinct from linked developmental phenotypes [61].
6. Place greater importance on the
significance of response to specific
treatments
1. Patients with anxiety and depression who fail to respond in the acute phase to CBT
but do respond to an SSRI or SNRI can be considered to be in a different category
[103,104,113];
2. Patients with psychomotor change or cognitive impairment who do not respond to
SSRI or SNRI but do respond to physical treatments such as electroconvulsive therapy
can be considered as a different category [64,120];
3. Patients with sleep or circadian disturbance who fail to respond to respond to CBT or
SSRI or SNRI but do respond to behavioral or pharmacological management that targets
the circadian system can be considered to be in a different category [121-124].
CBT: cognitive behavioral therapy; SNRI: selective norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.
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uals identified by health systems grows, and those with
less severe forms come into active clinical care, the extent
to which early forms of illness can be effectively managed
largely by non-pharmacological or other lifestyle-based ap-
proaches is a key consideration [66,129,130]. Critics of this
area [11,131] all too readily see an over-medicalization or
a pharmaceutical-industry-driven conspiracy to be at the
heart of such genuine public health movements. Yet the
evidence from the clinical staging of ischemic heart dis-
ease largely demonstrates the opposite. The greatest public
health emphasis was placed on reducing smoking rates,
promoting exercise and addressing other modifiable risks.
High cost, high risk interventions (for example, revascula-
rization) were reserved for those experiencing major
events (for example, first myocardial infarct), those with
recurring episodes (for example, coronary by-pass sur-
gery), or following a progression to chronic disease (for
example, pharmacotherapy of heart failure) [132,133].
Currently, the key difference between the diabetes and
early mental disorder arenas is the extent to which the
diagnosis of the ‘at-risk’ or ‘prodromal’ state for diabetes
relies on an independent laboratory test - and the extent
to which that laboratory test has predictive value forlater poor health outcomes. Therefore, concurrently with
the development and evaluation of earlier diagnostic
thresholds based on descriptive phenomena and related
disability estimates [22,52,53], we must intensify our
search for better neuropsychological, brain imaging, cir-
cadian, neurophysiological, immune or other markers of
these early states [58,59,72,76,99,106,134-136] and de-
sign studies to test their predictive capacity.
These new goals respond directly to the challenges posed
by novel preventive and longitudinal approaches that are
targeted at the recognition of early phenotypes. For ex-
ample, for depressive disorders, there is international rec-
ognition that the extraordinary premature death and
disability costs attributable to these conditions [48,137] re-
flect their early age-of-onset, high current and lifetime
population prevalence, typical illness patterns of recur-
rence and chronicity, and likely comorbidity with alcohol
and other substance misuse as well as physical ill-health,
most notably in the form of premature cardiovascular di-
sease [90,107,138-141]. The ways in which incorporating
these new goals might impact on the classification of de-
pressive disorders is outlined here (see Table 1).
As importantly, it is necessary to state those factors
which are not the primary goals of a clinical or research
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of abnormal perception, mood, cognition or other behav-
ioral disturbance; imposing independent category status
on disturbances that are fundamentally dimensional in na-
ture and frequently inter-correlated (see common forms
of anxiety and depression [142,143]); creating diagnostic
hierarchies that presume etiological or pathophysiological
dominance of one form of disturbance over another (for
example, psychotic compared with mood or cognitive
phenomena); or using the classification system as the sole
basis for allocating research funds, licensing treatments,
providing access to health care, determining legal matters,
reimbursing health care costs or supporting access to
other personal entitlements system.
Contrary to prevailing wisdom, there is no urgent need
to have one over-arching international diagnostic system
or bible for all perceptual, mood, cognitive and other be-
havioral syndromes. Unfortunately, the recent attempts
to include all things within the one descriptive system
have underpinned a rather unhelpful debate about the
inclusion or exclusion of fewer or more categories
[11,12,144]. Another unintended side-effect of the forced
international orthodoxy was the lack of support of other
plausible models or active support for the development
of alternative approaches [13,16,145].
An emerging body of work, utilizing appropriate genetic
modeling and brain imaging data provides provisional
support for such alternative approaches [20]. These data
favor a model in which mental disorders represent broad
patterns of psychopathology. Within this model, various
genetic and environmental factors determine the develop-
ment of common brain circuits that underpin normal
behavior and cognition. When perturbed, changes in
the function of these circuits give rise to deviant beha-
vior or cognitive function. This model has influenced the
National Institutes of Mental Health, which now actively
promotes investigation of brain-circuit-based approaches
and proposes that they may underpin a new approach to
the classification of common mental disorders [20,146].
Within the circuitry models, changes from normal func-
tion (thereby giving rise to disorders) are by their nature
dimensional rather than categorical. Generally, correla-
tions exist between the degree of accumulated dysfunction
of the underlying circuits (or related systems) and the ex-
tent of behavioral or cognitive change. This dimensional
approach shifts the emphasis from making a specific diag-
nosis to determining the current level of cognitive or
behavioral change in individual patients. Clinical and re-
lated neurobiological research then examines the extent to
which common risk variables (for example, developmental
delay, trait neurocognitive impairments, alcohol or other
substance misuse) increase risk to measured behavioral or
cognitive change, increase risk to markers of brain impair-
ment (for example, poor neuropsychological function,excessive cortical thinning, disturbed neurophysiological
markers) or increase risk to poor outcomes - indepen-
dently of any specific relationship with classical ‘diagnos-
tic’ entities [108,147,148].
Core dimensions of cognition and behavior are hy-
pothesized to be common to all persons and not viewed
as a unique set of characteristics occurring only in those
who present with mental health problems. Perturbations
of brain circuits will typically result in ‘trans-diagnostic’
rather than pathognomonic symptom sets. An important
prediction of such systems is that many objective mea-
sures of the structure (for example, brain imaging) or out-
puts of such systems (for example, cognition - including
traditional neuropsychological and social cognition,
circadian, hypothalamus-pituitary-adrenal axis function,
neurophysiological or immune) will also show little
diagnostic specificity. Over the last 30 years, this has
been the overwhelming experience with proposed diag-
nostic markers, such as the dexamethasone suppression
test for major depression [149]. Preliminary analyses of
data from those in the early phases of a range of major
psychotic or mood disorders also support this perspec-
tive [58-61,72,73,76,99,106,136,150,151].
New strategies for enhancing the diagnoses of
perceptual, mood, cognitive and other behavioral
syndromes
A range of diverse strategies can be advanced to support
these new goals (see Table 2). These do not need to come
together into one single bible for clinical or research pur-
poses, as the initial aim is to develop, evaluate and refine
them frequently as evidence emerges. A potential conse-
quence of the key shift from many categories to the use of
fewer underlying dimensions is that it is likely to lead to
the need for an alternative term to mental disorders. A
very broad descriptive concept that encapsulates a 21st
century approach to disturbances of perception, mood,
cognition and other behavioral dimensions may be re-
quired. The clear public, professional, clinical and research
benefits likely to derive from abandoning the historical
and cultural divisions between clinical neurology and
psychiatry and clinical psychology have been highlighted
by others [13,26].
In doing so, such strategies move away from the very
broad categories we currently use (for example, major
depression) to describe very heterogeneous populations.
Generally, more specific states (for example, depression
in association with late-life vascular disease; first episode
psychosis; cannabis-associated recurrence of psychosis;
depressive episode following previous manic episode)
provide a better fit with known risk factors, actual
pathophysiology or known illness course and may be
much more useful in research and some fields of clinical
practice [83].
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of-onset and stage-of-illness concepts should be recorded.
Those that have clear pathways to illness need to be em-
phasized (for example, childhood attention deficit hyper-
activity disorder leading to early age of onset of substance
misuse; childhood schizotypal or autistic behaviors leading
to early onset psychotic disorder; adolescent social anxiety
leading to alcohol misuse). Concurrently, this may help to
reduce the overuse of the concept of comorbidity - limit-
ing it in the future to the co-occurrence of genuinely inde-
pendent conditions (for example, psychotic disorder and
alcohol dependence).
It is clear that one of the most robust ways of differenti-
ating diagnostic groups is on the basis of response (or
non-response) to specific treatments. Much greater effort
needs to be invested in the reverse translation agenda
(that is, working back from the bedside to the bench). For
example, we urgently need to unravel what neurobio-
logical factors differentiate those with schizophrenia who
respond to clozapine or those with bipolar disorder who
respond to lithium. The goal is to develop better predic-
tors of treatment-response before initiating therapies.
At this time, we argue that we may be better served by
investing heavily in a much smaller number of more
discrete syndromes that are partially validated by clinical
course, objective markers or predictors of treatment
response. That is, rather than prioritize reliability, we
could vigorously pursue those more homogeneous groups
that are identified in clinical practice or family studies
[90-93]. Inevitably, this would advance the push for
more personalized approaches to health care. Further,
relevant groups could be preferentially recruited to spe-
cific preventive or treatment trials (for example, late-
onset depression; childhood-onset obsessive-compulsive
disorder; psychotic disorder preceded by childhood
schizotypal behaviors; first-episode mania; depressive
disorders characterized by disturbed hypothalamic-pituitary
function, circadian disruption or immune activation).
Another clear way of approaching this desire for greater
specificity is to focus on syndromes that are closely linked
with discrete environmental exposures, social adversity or
inter-current medical events [152]. These natural experi-
ments can be used to facilitate more targeted pathophysio-
logical studies (for example, post-infective or post-stroke
neuropsychiatric syndromes; post-traumatic depressive
states; depression or prolonged fatigue states following
cancer therapies; alcohol or other substance misuse neu-
ropsychiatric syndromes; cannabis-associated first episode
of psychosis [89,153-156]).
We would also promote an overt move away from
checklist-driven criteria that rely on poorly validated
symptom sets (for example, treating independent symp-
toms such as sleep disturbance and suicidal ideation as
equivalent items for the diagnosis of major depressivedisorders). Instead, we favor a move back towards clear
syndromes that share key pathophysiological, symptom
or illness course features (for example, psychotic depres-
sion; melancholic disorders that are associated with con-
current psychomotor change; first-episode psychosis;
bipolar disorder diagnosed by a discrete manic episode).
This process would also be assisted by greater use of ob-
jective markers of key features of disorders (for example,
computer-generated measures of neurocognitive func-
tion; actigraphy-generated measures of sleep-wake cycle;
self-report based measures of cognitive styles) and wider
use of clinician or self-reported measures of key symp-
tom dimensions.Promoting the use of clinical staging
One of the most important developments in recent years
has been the importing of the concept of clinical staging
from general medicine. In other clinical domains (for ex-
ample, oncology, coronary heart disease, inflammatory
join disease), it is totally inadequate to choose treatments,
or plan health care, for persons who suffer from recurring
or progressive conditions simply on the basis of a broad
diagnostic category (for example, breast cancer). We sug-
gest that it is equally meaningless in mental health to se-
lect specific treatments on the basis of broad categories
such as schizophrenia, bipolar disorder or major depres-
sion. There is a wealth of evidence indicating that patients
at different points along the illness continuum of all of
these conditions show quite different patterns of response
to various interventions [21,88,157,158].
Consequently, we have proposed a general framework
for clinical staging that can be applied to the more se-
vere mood or psychotic disorders (Figure 1). This frame-
work is readily applied to those who present for health
care and clearly differentiates those in early phases
(stages 1a ‘seeking help’ or 1b ‘attenuated syndromes’)
from those who have reached a higher threshold for dis-
order (stage 2 and above - see Figure 1). Current clinical
and related neurobiological studies (for example, magnetic
resonance imaging; neuropsychological and sleep/circa-
dian studies) of this framework provide provisional evi-
dence in support of its reliability and validity [22,58,59].
As compared with current DSM and ICD disorder
thresholds, and particularly for the common anxiety and
depressive disorders, this approach raises the bar for the
initiation of more specific or intensive pharmacological
or behavioral strategies. That is, although this approach
does encourage more active health care for those at
lower levels of illness, it also promotes the use of safe,
easily-delivered and non-specific psychological interven-
tion, health-care, suicide prevention and other secondary
prevention strategies for those who have not yet reached
the higher threshold for a stage 2 disorder [54,84].
Figure 1 A clinical staging model for post-pubertal onset and course of major mental disorders: developmental, circadian or anxiety
pathophysiological pathways progress from non-specific to discrete syndromes. *Not necessarily a Diagnostic and Statistical Manual for
Mental Disorders, fourth edition, or International Classification of Diseases - 10th revision diagnosis; GM: gray matter; WM: white matter.
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dimensions and linking these to clinical staging
All of these strategies move the emphasis from the ra-
ther sterile academic debates about the virtues of com-
peting symptom sets (or illness thresholds) [159-161] to
the provision of relevant treatment at key points along
an illness path. In dialogue with individual patients, this
would result in the provision of far more accurate,
multi-dimensional and context-relevant information. In
our view, stating clearly that a 21-year-old man has a
first-onset psychosis, with a strong family history of
mania and associated five-year history of persistent can-
nabis use is more likely to guide treatment selection,
health care planning and accurate prognostic statements
than assigning any of the current psychosis disorder
categories. Similarly, stating that a 17-year-old girl has the
recent onset of a depressive disorder characterized by psy-
chomotor slowing and preceded by prolonged fatigue, sea-
sonal changes in mood and energy, with no evidence of
childhood anxiety or concurrent alcohol or substance mis-
use is more useful than attaching any of the current de-
pression categories. While these approaches are already
common in everyday clinical practice they are not cap-
tured in our current diagnostic systems.
Further, we need systems that support innovative re-
search paradigms such as those promoted by the youth
mental health for common mental disorders and early
intervention in psychosis movements [162,163]. Within
these novel paradigms, it is far more important to re-
cruit patients who share key demographic, illness stage,
prior treatment characteristics or family history (for ex-
ample, age, gender, duration of illness, lack of priorexposure to medical treatments, family history of psych-
osis or mania) rather than pre-selecting on the basis of
poorly-validated syndromal constructs such as major
depression.
Such novel research paradigms inevitably focus atten-
tion on those genetic or environmental risk factors that
are common across disorders (and hence may be modified
with resulting benefits to a large number of persons), dis-
tinct from the narrow search for unique risk factors that
link specifically to each separate disorder. Key consi-
derations such as the role of intra-uterine environments,
early childhood infections, childhood sexual or emotional
abuse, early adolescent alcohol or substance misuse, grossly
distorted adolescent sleep patterns, and physical inactivity
in the teenage years will then emerge as major foci for
targeted research and potential public health programs
[58,60,108,164-166].
Implications for clinical research and reverse translation
These alternative approaches to classification would give
rise to a new wave of early intervention, biomarker, clinical
intervention and other longitudinal studies. Specifically,
they would also promote reverse translation initiatives -
meaning those research programs that work back from
clinical research based on well-characterized, more narrow
and probably more homogeneous patient groups to eluci-
date more fundamental biological correlates. Additionally,
the reverse translation agenda has other important attri-
butes, including actively responding to topics of real signifi-
cance to those living with the illness (for example, cognitive
impairment in those with psychotic disorders) and capital-
izing on phenomena that have been well-replicated in
Table 3 Reverse translation research agenda for circadian-based mood disorders
Reverse translation strategies Specific research studies
1. Identify cohorts with clear indicators of circadian-
based pathophysiology [58,60,99,167,168]
1. Establish relevant clinical cohorts. For example:
a. early-onset depression with family history of mania;
b. less than 10 years of active illness with lithium-responsive mania;
c. early-onset depression with evidence seasonal change in disorder severity or
preferential response to behavioral or pharmacological circadian-based
interventions;
2. Introduce circadian-based phenotypes or markers to other relevant
epidemiological, clinical or longitudinal studies. For example:
a. sleep-wake cycle and circadian phenotypes into relevant developmental, family,
genetic or twin studies;
b. sleep-wake cycle and circadian phenotypes into relevant population-based
studies of illness-onset or course.
2. Introduce specific biomarker strategies to the study
of cohorts with circadian-based pathophysiology
Introduce objective markers of 24 sleep-wake and circadian activity cycle to
descriptive, longitudinal and interventional studies. For example:
a. use of smart-phone technologies to track sleep cycles;
b. use of ecological monitoring application technologies to study behavioral
rhythm patterns;
c. use of actigraphy to study timing and stability of activity cycles;
d. use of dim-light melatonin assays to study patterns of melatonin onset.
3. Design prevention or clinical intervention studies
that are relevant to cohorts characterized by circadian-
based dysfunction (for example [104,123,125,169-175])
Trial designs include:
a. selection of young patients with depressive disorders and concurrent phase-
delay syndromes for evaluation of efficacy of circadian-based behavioral
interventions, light therapy, melatonin or agomelatine, remelton or tasimelteon;
b. selection of young patients with depression and phase-delay, and family
history of mania or psychosis or family history of response to lithium, for
evaluation of behavioral or pharmacological strategies to prevent first episode of
mania;
c. evaluating whether those with bipolar disorder who are most responsive to
lithium also have depressive disorders that are preferentially responsive to light
therapy, melatonin or agomelatine;
d. evaluating the effects of circadian-based interventions on the course of
metabolic parameters in young persons treated for depression or bipolar
disorder.
4. Initiate specific genetic or pathophysiological studies
in those with specific circadian-parameters [176,177]
Examples include:
a. specific genetic association for circadian markers in those cohorts who are
responsive to lithium or other circadian-specific interventions;
b. specific genetic association for circadian markers in family members of those
with lithium-responsive bipolar disorder;
c. specific genetic association for circadian markers in family members of those
with depression who are responsive to light therapy, melatonin or agomelatine;
d. evaluate the capacity of cross-sectional and longitudinal dim-light melatonin
onset assays to predict the response to treatment or rate of recurrence in those
with circadian-based depressive disorders;
e. evaluate the capacity of cross-sectional and longitudinal dim-light melatonin
onset assays to predict the response to treatment or rate of recurrence in those
with bipolar disorders.
5. Designing relevant animal model systems to evaluate
the likely therapeutic effect of novel behavioral or
pharmacological interventions or better understand the
effects of effective interventions on the circadian clock
[122,178-180]
1. Development of Zebra fish based assays of effects of differing pharmacologies
on circadian-dependent locomotor function in fish larvae;
2. Design studies using effective circadian therapies for mood disorders (as
defined by human response) in genetically-informative mice to study changes in
underlying mechanisms of the circadian clock and its output systems;
3. Test novel pharmacological strategies (that is, agents which target molecular
mechanisms of the circadian clock) in animal models of depression.
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Table 3 Reverse translation research agenda for circadian-based mood disorders (Continued)
6. Development of novel biomarkers of the circadian
system for use in risk factor and treatment systems (for
example, [181-185])
1. Optimization of measurements of circadian disruption in humans with major
affective disorders, via new systems and technologies (for example, circadian
phase in fibroblasts) - with a focus on easy repeatable measures not only of
phase-shifts but also internal desynchrony;
2. Relating measures of disruption of the circadian systems to other measures of
chronic distress (for example, hair cortisol measures).
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disorder or clozapine-responsive schizophrenia).
The combination of key clinical insights and patient
priorities plays a crucial role in setting the reverse transla-
tion research agenda [2]. Categories deserving of detailed
neurobiological research are those clinical situations in
which a robust link with relevant pathophysiological,
risk, illness-stage or treatment variables has already been
demonstrated (for example, circadian-based depressive
disorders - see Table 3; cannabis-associated psychosis;
first-episode mania; or clozapine-responsive schizophrenia
disorders).
On the basis of making new links in these smaller but
clinically-defined cohorts with the best available markers
of the active pathophysiology, we would then expect
new insights that could provide a basis for working for-
wards again (that is, bench back to bedside). A new wave
of more relevant animal models, molecular targeting or
other rapid assay modalities could emerge. The goal
then is to use that new knowledge to implement better
targeted and more individualized prevention or active
treatment strategies (that is, traditional forward transla-
tion programs [167,186-188]). Such translational re-
search programs (that is, those that incorporate both
reverse and forward strategies) would then genuinely
link 21st century neurobiology to clinical practice in an
iterative and mutually-informative discourse.
The impact of the move away from investigating trad-
itional schizophrenia to more focused first-episode
psychosis (and then related prodromal or at-risk clinical
research) in Australia, Europe and the United Kingdom
demonstrates the extent to which these novel ap-
proaches can genuinely transform clinical practice
[27,56,163]. By contrast, those working in the anxiety
and mood disorders fields have been slow to compre-
hend the significance of these developments [28,85]. We
believe the time is now right for a more general shift in
direction in favor of those diagnostic practices that focus
attention on key developmental, illness course, reverse
translation and strategic intervention approaches. Al-
though we can recognize the genuine progress that the
DSM and ICD revisions from 1980 onwards supported,
there is now no longer any good reason for the inter-
national mental health community to be constrained by
the ongoing revisions of these systems.Summary
After 30 years of consensus-based diagnostic categories in
mental health, there is great clinical and public frustration
with our relative failure to deliver real clinical advances.
The approach introduced by the DSM-III (1980) priori-
tized reliability and imposed a categorical approach on
many underlying dimensions of abnormal cognition,
mood or behavior. It also sought to ‘cover the field’ and in
doing so gave rise to new entities for further research and
evaluation. The general approach enhanced epidemiology,
international collaboration and health services planning,
but too little progress has been made with linking the
multiple broad entities to clear genetic or environmental
risk factors, underlying pathophysiology or specific pat-
terns of treatment response. Consequently, we have ar-
gued that it is time to prioritize the validation of more
robust clinical entities and foster the development of spe-
cific strategies to support this priority. The proposed goals
put enhanced clinical practice back at the center of the en-
deavor, work with strong cross-sectional and longitudinal
epidemiological, family and twin studies, and use available
objective markers. The value of implementing new dimen-
sions, notably clinical staging, that are both clinically rele-
vant and directly related to emerging epidemiological,
developmental and neurobiological research is also pro-
posed. The strategies described abandon the historical and
cultural divides between clinical neurology, psychiatry and
psychology and actively move away from broad descriptive
terms (for example, major depression, schizophrenia, bi-
polar disorder) to the promotion of pathways to illness
models. These models incorporate age-of-onset, known
environmental risk factors and patterns of response to
specific treatments (for example, lithium-responsive bipo-
lar disorder, clozapine-responsive psychosis). A strong em-
phasis on a reverse translation agenda (that is, working
back from the clinic to the laboratory) is highlighted. This
agenda relies on using diagnostic groupings that already
have strong evidence of links to specific risk factors or pat-
terns of treatment response. We have detailed the ways in
which these approaches could enhance clinical practice in
the most impactful of the major mental disorders, namely
major depression. In this worked example, the term major
depression would largely be replaced by much more
specific terms that differentiate early- from late-onset,
those presentations that fundamentally followed-on from
Hickie et al. BMC Medicine 2013, 11:125 Page 10 of 14
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linked with objective measures of circadian disturbance.
As with all other disorders, clinical staging of depressive
disorders would also clearly differentiate early-attenuated
forms from first major episodes of illness (both typically
occurring in adolescence or early adult years) and later re-
current, persistent or chronic forms.
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